GT Biopharma, Inc. (GTBP) vs KALA BIO, Inc. (KALA)
A side-by-side comparison of GT Biopharma, Inc. and KALA BIO, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GTBP
GT Biopharma, Inc.
$6.30HealthcareDelayed quote: Oct 6, 2026, 12:09 PM EDT
KALA
KALA BIO, Inc.
$0.37HealthcareDelayed quote: Oct 6, 2026, 12:08 PM EDT
Total return — GTBP vs KALA
growth of $100 · dividends reinvested · last 9yGTBP -100.0% (-65.0%/yr)KALA -100.0% (-72.9%/yr)GTBP compounded faster over this window
Log scale — wide-divergence pair
GTBP KALA
GTBP vs KALA: by the numbers
- •GTBP is the larger company ($8M vs $7M market cap).
Metrics side by side
Valuation
| Metric | GTBP | KALA |
|---|---|---|
| P/B ratio | 2.23 | 0.78 |
Profitability
| Metric | GTBP | KALA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -618.74% | -111.46% |
| ROIC | -457.75% | -232.05% |
Growth (annualized)
| Metric | GTBP | KALA |
|---|---|---|
| Total return CAGR (5Y) | -73.13% | -85.73% |
Frequently asked
- How have GTBP and KALA total returns compared?
- Over the past 5 years, GTBP delivered -73.13% and KALA delivered -85.73% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.